D DIAMEDICA THERAPEUTICS INC
| Market Cap | $349.16M |
| P/E Ratio | — |
| Forward P/E | -7.75 |
| Dividend Yield | — |
| Beta | 1.15 |
| 52W Range | $3.38 - $9.39 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Leon Cooperman Cooperman Leon G | 0.53% | $16.08M | 2,020,000 | Reduce 38.22% |
Insider Trading
| Insider Name of the company insider who made the trade 7 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| STAHLBERG JAN | Buy | 73,099 | $8.57 | $626.82K | 25 Nov 2025 | 08 Dec 2025 |
| STAHLBERG JAN | Buy | 40,253 | $7.89 | $317.72K | 24 Nov 2025 | 08 Dec 2025 |
| STAHLBERG JAN | Buy | 208,872 | $7.41 | $1.55M | 21 Nov 2025 | 08 Dec 2025 |
| STAHLBERG JAN | Buy | 128,426 | $7.41 | $951.21K | 20 Nov 2025 | 08 Dec 2025 |
| STAHLBERG JAN | Buy | 240,352 | $7.21 | $1.73M | 19 Nov 2025 | 08 Dec 2025 |
| STAHLBERG JAN | Buy | 182,882 | $6.75 | $1.23M | 18 Nov 2025 | 08 Dec 2025 |
| STAHLBERG JAN | Buy | 187,393 | $6.52 | $1.22M | 17 Nov 2025 | 08 Dec 2025 |
Frequently Asked Questions
What is DMAC stock price today?
DIAMEDICA THERAPEUTICS INC (DMAC) is currently trading at $6.48. The stock has a 52-week range of $3.38 to $9.39 and a market capitalization of $349.16M.
Is DMAC a good stock to buy in 2026?
DIAMEDICA THERAPEUTICS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +76.1%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling DMAC stock?
There have been 7 insider transactions for DMAC in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has DMAC stock performed over the past year?
DIAMEDICA THERAPEUTICS INC (DMAC) has returned +76.1% over the past 12 months. The stock traded between $3.38 and $9.39 during this period, and is currently at $6.48.
Which hedge funds own DMAC (DIAMEDICA THERAPEUTICS INC)?
1 tracked hedge funds currently hold DMAC in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is DMAC's market cap and valuation?
DIAMEDICA THERAPEUTICS INC (DMAC) has a market capitalization of $349.16M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is DMAC's revenue and profitability?
DIAMEDICA THERAPEUTICS INC reported revenue of N/A with net income of N/A and a profit margin of N/A. The stock has a beta of 1.15.
What sector is DMAC in and who are its biggest institutional holders?
DIAMEDICA THERAPEUTICS INC (DMAC) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.